Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
132.60
-0.22 (-0.17%)
May 5, 2025, 4:00 PM EDT - Market closed
Abbott Laboratories Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Abbott Laboratories stock have an average target of 140.44, with a low estimate of 120 and a high estimate of 160. The average target predicts an increase of 5.91% from the current stock price of 132.60.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Abbott Laboratories stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 6 | 6 | 6 |
| Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $132 → $142 | Buy | Maintains | $132 → $142 | +7.09% | Apr 17, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $133 → $145 | Buy | Reiterates | $133 → $145 | +9.35% | Apr 17, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $140 → $145 | Buy | Maintains | $140 → $145 | +9.35% | Apr 17, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $136 → $147 | Buy | Maintains | $136 → $147 | +10.86% | Apr 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $117 → $127 | Hold | Maintains | $117 → $127 | -4.22% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
45.08B
from 41.95B
Increased by 7.45%
Revenue Next Year
48.55B
from 45.08B
Increased by 7.70%
EPS This Year
5.21
from 7.64
Decreased by -31.87%
EPS Next Year
5.74
from 5.21
Increased by 10.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.3B | 51.5B | 56.1B | ||
| Avg | 45.1B | 48.5B | 52.2B | ||
| Low | 43.3B | 46.5B | 49.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.7% | 14.3% | 15.5% | ||
| Avg | 7.5% | 7.7% | 7.5% | ||
| Low | 3.3% | 3.0% | 2.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.50 | 6.11 | 6.88 | ||
| Avg | 5.21 | 5.74 | 6.34 | ||
| Low | 4.98 | 5.45 | 5.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -28.0% | 17.5% | 19.9% | ||
| Avg | -31.9% | 10.2% | 10.5% | ||
| Low | -34.8% | 4.7% | 3.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.